Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | JAK3 | P52333 | 4/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | PGAM1 | P18669 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158506 | 0.86 | CYBB (0.41) | CYBBNMT1ABL1BCRCCR2 | |
| SCHEMBL15753432 | 0.86 | CYBB (0.44) | CYBBNMT1CCR2PIK3C3ADORA2A | |
| SCHEMBL14158918 | 0.84 | CYBB (0.55) | CYBBNMT1ABL1BCRCCR2 | |
| SCHEMBL14158643 | 0.82 | ROCK1 (0.46) | CYBBROCK2ROCK1CDC42BPB | |
| SCHEMBL14158736 | 0.82 | CYBB (0.67) | CYBBNMT1ABL1BCRCCR2 | |
| SCHEMBL14158798 | 0.81 | CYBB (0.52) | CYBBNMT1ABL1BCRCCR2 | |
| SCHEMBL14158590 | 0.81 | CYBB (0.68) | CYBBNMT1ABL1BCRCCR2 | |
| SCHEMBL14158705 | 0.80 | CYBB (0.69) | CYBBCCR2PIK3C3 | |
| SCHEMBL14158521 | 0.78 | CYBB (0.56) | CYBBKITJAK2JAK3PTK2 | |
| SCHEMBL14158967 | 0.77 | GHSR (0.38) | ABL1BCRJAK2PGAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | CYBB 1/4885NMT1 776/4885ABL1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.